electroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
electroCore (Nasdaq: ECOR) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. Management presentation is scheduled for 2:15 pm ET, led by Joshua Lev, Interim President and Chief Financial Officer.
Investors can request one-on-one meetings via their Needham representative or by emailing investors@electrocore.com.
Positive
- None.
Negative
- None.
News Market Reaction – ECOR
On the day this news was published, ECOR declined 7.45%, reflecting a notable negative market reaction. Argus tracked a peak move of +13.9% during that session. Argus tracked a trough of -3.3% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $5M from the company's valuation, bringing the market cap to $58.93M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ECOR shows a -4.69% move with mixed peers: NMTC is up 2.43%, while IINN, MODD, MYO, and RBOT are down between -1.75% and -4.90%, suggesting stock-specific factors rather than a uniform sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | Clinical publication | Positive | +9.4% | Post-hoc analysis of 35 mTBI/PTSD patients showed symptom reduction with nVNS. |
| Mar 31 | Exec hires & grants | Positive | +6.9% | New VP Sales and COO with 100,000 RSUs granted under inducement awards. |
| Mar 30 | Patent expansion | Positive | -3.8% | Two new U.S. patents expanded protection for nVNS platforms into the 2040s. |
| Mar 19 | FY25 earnings | Positive | -4.7% | Record $32.0M net sales, improved EBITDA loss, and ~30% 2026 growth guidance. |
| Mar 10 | Conference participation | Neutral | -2.1% | Management participation at the 38th Annual Roth Conference with investor meetings. |
Recent positive operational and clinical updates often led to upside, while patents and earnings drew negative reactions, and conference participation saw a modest decline.
Over the past month, ECOR reported a range of developments. An mTBI/PTSD nVNS publication on April 1, 2026 and executive inducement grants on March 31, 2026 were followed by gains of 9.45% and 6.91%. New patents announced on March 30, 2026 and full-year 2025 results on March 19, 2026 saw declines of 3.75% and 4.65%. A prior conference participation notice on March 10, 2026 coincided with a 2.11% drop, framing today’s Needham conference update within a pattern of mixed reactions.
Regulatory & Risk Context
An effective resale registration filed on October 3, 2025 covers up to 762,508 existing common shares for selling stockholders. The company indicated it is not issuing new securities under this S-3 and will not receive proceeds from these resales, though registered shares can add tradable supply.
Market Pulse Summary
The stock moved -7.5% in the session following this news. A negative reaction despite this routine conference update would fit past patterns where even constructive news, like record $32.0M 2025 sales, saw a -4.65% move. Filings flag dependence on large customers, capital needs, and an equity deficit, and a resale registration for 762,508 shares exists. These structural risks could reinforce pressure when sentiment weakens, even on neutral announcements.
AI-generated analysis. Not financial advice.
ROCKAWAY, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 15, 2026.
Joshua Lev, Interim President and Chief Financial Officer, will host a company presentation at 2:15 pm ET and participate in one-on-one meetings throughout the day.
DATE: April 15, 2026
TIME: 2:15 pm ET
Investors attending the conference who are interested in scheduling a meeting with management can do so by contacting their Needham representative, or by emailing ECOR Investor Relations at investors@electrocore.com.
About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
